Free Daily Podcast Summary
HemaSphere Podcast: Daily Summaries Delivered
by HemaSphere Journal
HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 weeks ago39 min
CAR T From Within - Vilcot, Brugère, Fuentealba, Houot
Could making CAR T cells directly inside the patient change how treatment is delivered? Scientific Editor Dr Charles De Bock joins Prof Roch Houot, Dr Jaime Fuentealba, François Vilcot, PharmD, and Carole-Anne Brugère, PharmD, to explore the promise and challenges of in vivo CAR therapy. They compare delivery approaches, examine safety and targeting, and discuss potential gains in access alongside uncertainty over costs. Listen for a multidisciplinary perspective on what comes next.Read the referenced Review Article here: https://bit.ly/4d1mfjPKey topicsHow in vivo CAR therapy differs from conventional CAR T manufacturingLentiviral vectors and lipid nanoparticles: targeting, persistence, and safety, including the need for long-term monitoringClinical translation, scalability, and why simpler delivery may not mean lower pricesEurope’s role in development and lessons from writing a multidisciplinary reviewTimestamps00:00 — Why in vivo CAR is attracting attention now 02:37 — What it means to manufacture CAR T cells inside the patient 05:29 — Three layers of specificity for lentiviral delivery 10:08 — Why modern lentiviral vectors are safer than early gene therapy vectors 14:41 — How lipid nanoparticles can target T cells and avoid the liver 16:26 — Whether transient CAR expression can still be therapeutic 19:10 — Choosing between lentiviral vectors and lipid nanoparticles 22:53 — The hardest unsolved problem: balancing efficacy, safety, and scalability 23:18 — Site-specific gene editing and TRAC locus insertion 26:21 — Industry momentum and whether in vivo CAR can lower cost 28:40 — Europe’s opportunity in clinical translation 31:23 — What to expect from upcoming ASH and other conference data 35:05 — How the multidisciplinary review was scoped and organized 37:09 — Why figures were designed early in the writing process 39:57 — Advice for PhD students writing a review in a fast-moving field
- Sep 10, 202640 min
Why More Mitochondrial DNA Mutations Can Mean a Better Outcome - Dr Ilaria Pagani
This episode explores how chronic myeloid leukemia has been transformed by imatinib and other TKIs, while also showing why major clinical challenges remain for the patients who do not respond well or want to stop therapy. Host Scientific Editor Dr Charles de Bock talks with Dr. Ilaria Pagani about her recent HemaSphere paper on mitochondrial DNA mutations, oxidative phosphorylation, and treatment response in CML, and why mitochondria may be an overlooked source of biomarkers and new targets. We discuss the biology of relapse, why some patients can achieve treatment-free remission, and how mitochondrial metabolism may help explain differences between poor responders and super responders. The conversation also touches on patient advocacy, quality of life, and the need for more collaborative, metabolism-focused research.Read the article in full, open access: https://hsphere.pub/448You've read the paper, now hear the story.
- Jun 17, 202638 min
Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel
In this episode, host Dr Charles de Bock delves into groundbreaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in MDS with Dr Manja Wobus and Dr Katja Sockel. Join us as we unpack the mechanisms, animal studies, and future clinical prospects for this promising therapy.Read the accompanying article published in HemaSphere https://bit.ly/3OjuuiSi4MDS, EHA's Specialized Working Group information https://hsphere.pub/5d4
- May 7, 202636 min
p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór
Discover the latest insights into the multifaceted role of p53 in normal hematopoiesis and its critical involvement in myeloproliferative neoplasms (MPNs). This episode features Dr. Isabelle Plo and Dr. Barbara Monte-Mór sharing their expertise on TP53 mutations, molecular mechanisms driving leukemic transformation, and emerging therapeutic strategies targeting p53.Article: https://bit.ly/4sZbo01Comments, Suggestions or Feedback? Please take a few minutes and let us know: https://wkf.ms/4pDYjYb
- Feb 9, 202646 min
Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood
In this episode, host HemaSphere Scientific Editor Dr Charley de Bock speaks with Associate Professor Dr Matthew Greenwood about the SUBLIME (ALL09) trial, which explores replacing consolidation chemotherapy with blinatumomab in adolescents and young adults with B‑cell ALL. They discuss why immunotherapy may outperform traditional cytotoxic approaches, how MRD‑guided treatment is reshaping risk stratification, and what future protocols might look like as genomic and immune‑response data are integrated in real time. Dr. Greenwood also shares upcoming innovations—including menin inhibitors, venetoclax‑based MRD targeting, and adaptive platform designs—along with honest insights into the challenges of running clinical trials across Australia.
- Dec 2, 202555 min
Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate
In this extended episode of the HemaSphere podcast, based on a must-read Perspective "Can health inequalities in sickle cell disease be addressed through novel therapies?", our host Scientific Editor Charles de Bock discusses sickle cell disease with co-authors, covering both expert and lived-patient perspectives. They explore the complexities of living with the disease, the current treatment landscape, and highlight the ongoing health inequalities faced by patients, the impact of withdrawn therapies, and the need for improved communication and trust between patients and healthcare providers.Further information:No One's Listening ReportShaniqua's Sickle ChroniclesNICE (National Institute for Health and Care Excellence)UK NHS blood donationPlease take a few minutes and let us know what you think about this episode! Podcast Feedback
- Nov 3, 202535 min
Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD
Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD, join Dr. Charles de Bock to unpack the challenges of diagnosing and treating acute leukemias of ambiguous lineage (ALAL). Discover how RNA sequencing, machine learning, and collaboration are shaping the future of precision medicine in hematology. 🎧 Listen and then read the full open-access article on the HemaSphere website https://bit.ly/4oeJo6w
- Oct 1, 202540 min
EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski
Join our host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski, first author of this 2025 HemaSphere Top Cited –Clinical Award-winning paper. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities and the need for a structured grading system.EHA/EBMT Survey on Grading and Management of ICAHT, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube. Listen and enjoy casual, insightful discussions about #hematology research.You can find the referenced article, in full and open access, here on the HemaSphere website.
Get HemaSphere Podcast summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Health Optimization Medicine Podcast
Experts discuss science-based strategies for health optimization, performance, and human potential through targeted interventions.
In the Interim...
Explores Bayesian statistics and adaptive clinical trial designs in medical research with insights from industry experts.
Pathogen Perspectives
pathogenperspectives
Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.
ScienceSphere
A weekly exploration of scientific discoveries across physics, biology, astronomy, and technology, explained clearly for all listeners.
Our Skin: A Personal Discovery Podcast
People share personal experiences with skin conditions like psoriasis and HS, discussing diagnosis, treatment, and living fully despite challenges.
A Shot in the Arm Podcast
Ben Plumley
The BioHub - by Avetix
Conversations with leading biotech experts reveal the strategies and stories driving innovation in the biotechnology industry.
Frankly Speaking About Family Medicine
Discusses current topics and developments in primary care and family medicine.
Health vs Hype with the American Medical Association
A medical expert debunks viral health trends and misinformation with science-backed insights from physicians.
Extend Podcast with Darshan Shah, MD
Explores science-backed strategies and expert insights to extend healthspan and optimize longevity through actionable health protocols.
Phenomena Podcast: The Science & Stories of Energy Healing
Explores scientific research and personal stories behind energy healing practices like reiki and qigong.
About HemaSphere Podcast
HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from HemaSphere Podcast in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's HemaSphere Podcast daily summary?
It's a free AI-powered email that summarizes new episodes of HemaSphere Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the HemaSphere Podcast podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official HemaSphere Podcast product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by HemaSphere Journal.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does HemaSphere Podcast release new episodes?
HemaSphere Podcast publishes monthly. Our AI generates a summary within hours of each new episode.
What topics does HemaSphere Podcast cover?
HemaSphere Podcast covers topics including Science, Medicine, Fitness, Health & Fitness, Natural Sciences, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting HemaSphere Podcast summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.